Short answer
Verastem, Inc. (VSTM) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $24M (up 113.6% year over year) with net income of −$75M.
Q3 2026 key financials · XBRL
- Revenue
- $24M
- +113.6% YoY · −40.1% QoQ
- Net income
- −$75M
- +24.2% YoY · −115.5% QoQ
- Operating margin
- -313.3%
- EPS (diluted)
- −$0.74
- +43.9% YoY · −111.4% QoQ
Source: XBRL data from the Verastem, Inc. (VSTM) Q3 2026 10-Q on SEC EDGAR. USD.
Verastem, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $24.0M, up 114% YoY from $11.2M, driven by AVMAPKI FAKZYNJA CO-PACK shipments
- Product gross margin 84.7% vs 85.1% YoY, based on revenue and product cost figures
- Best growth: VS-7375 clinical R&D $25.9M, up 1891% from $1.3M
- Cash, equivalents and investments $172.8M; operating cash outflow $129.6M vs $107.6M YoY
- Near-term funding through October 2026 offering, expected product revenue and existing resources; FDA blister-pack decision by February 7, 2027
Risk Factors
- No material risk-factor changes identified, with the 10-Q directing investors to the 2025 Form 10-K
- Cash burn risk: operating cash use increased to $129.6 million from $107.6 million
- Debt interest-rate risk: $75.0 million of Initial Notes carry floating-rate interest
- Market risk: $172.8 million held in cash, equivalents and investments exposed to interest-rate changes
- Foreign-currency risk: CRO and manufacturer contracts may be denominated in foreign currencies
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Verastem, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.